Neal Flomenberg, who serves as Chief Scientific Officer and Global R&D Lead at Tevogen Bio Holdings Inc (NASDAQ:TVGN), reported the sale of 972 shares of common stock over a four-day period in March 2026. The transactions, recorded in a Form 4 filing with the Securities and Exchange Commission, span March 10 through March 13 and amount to approximately $6,635 in proceeds.
The Form 4 details the breakdown of the sales. On March 10, Flomenberg sold 19 shares at a price of $7.75 per share. On March 11, he disposed of 452 shares across multiple transactions with execution prices ranging from $7.25 to $7.33. The final set of transactions occurred on March 13, when 501 shares were sold in several tranches at prices between $6.39 and $6.74.
The filing states these sales were not discretionary. Instead, they were carried out to satisfy tax obligations arising from the vesting and settlement of restricted stock units. After these transactions, Flomenberg is shown as directly owning 76,940 shares of Tevogen Bio Holdings Inc.
The company’s stock has been trading near its 52-week low of $4.92, according to InvestingPro. This trading level and related market dynamics were noted in the filing and in subsequent reporting concerning analyst coverage and corporate actions.
In other corporate developments, Tevogen’s board of directors has stated it will assess whether to declare a one-time special cash dividend for shareholders. The board indicated that such a dividend would be conditional on meeting specified financial milestones, which may include revenue and earnings targets to be determined at a later date. No specific milestones or timelines were provided in the disclosures.
Additionally, D. Boral Capital adjusted its outlook for Tevogen by lowering its price target from $5.00 to $2.00 while maintaining a Buy rating on the stock. The firm cited an increased risk of dilution stemming from the company’s declining share price as the rationale for the reduction in target.
Taken together, the insider sale to cover tax liabilities, the board’s evaluation of a potential special dividend contingent on future financial performance, and the analyst’s reduced price target are developments investors and market participants will weigh when assessing Tevogen’s near-term financial strategies and valuation.